Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

The investigators will draw blood from the subject to make EBV-specific cytotoxic T-lymphocytes (EBVSTs) in the lab. Investigators will make the cells by first growing a special type of cells called dendritic cells (DCs) or monocytes to stimulate the T cells. Then they will add specially produced mixtures of proteins that included the LMP, EBNA1, and BARF proteins. These are used to stimulate T cells. As the T cells grow, investigators add some of the subject's cells expressing these proteins to stimulate them. They also add a cell called K562 that has had new genes put inside it so it expresses proteins that stimulate the immune system to encourage the T cells to grow. This stimulation trains the EBVSTs to kill cells with EBV proteins on their surface. These cells will be grown and frozen.

The cells grown in the lab will be thawed and injected into the subject's vein over 2-10 minutes. Initially, one dose of the drug nivolumab is given one day before the EBVST cells are infused (on day 0) and then every 2 weeks for a total of four doses of nivolumab. Subjects will receive two infusions of the EBVST cells. The first infusion will be given on Day 1 and a second infusion of T cells on Day 15.

If eligible, subjects may receive up to three additional doses of the T cells 6-12 weeks apart and each additional T cell infusion would be preceded by one dose of nivolumab a day prior.

Subjects will have medical and blood tests at predetermined time points. Investigators will follow subjects closely after treatment for any side effects for at least for 1 year after the subject's last infusion.

Inclusion criteria

PROCUREMENT Inclusion

• Any patient, regardless of age* or sex, with measurable EBV-positive Hodgkin's or non-Hodgkin's Lymphoma, (regardless of the histological subtype)^ or EBV (associated)- T/NK- or B cell lymphoproliferative disease

• The first 3 patients enrolled will be adults. Patients <18 years of age are eligible if those first 3 patients do not experience dose limiting toxicity considered to be primarily related to the EBVST or Nivolumab.

^ Patients with relapsed or refractory lymphoma who failed or are ineligible for an autologous hematopoietic cell transplantation are also eligible for this study.

• EBV positive tumor (can be pending)
• Weighs at least 12kg
• Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given a copy of informed consent.
• Life expectancy of greater than 6 weeks.

TREATMENT Inclusion

• Any patient, regardless of age* or sex, with measurable EBV-positive Hodgkin's or non-Hodgkin's Lymphoma, (regardless of the histological subtype)^ or EBV (associated)-T/NK- or B cell lymphoproliferative disease

• The first 3 patients enrolled will be adults. Patients <18 years of age are eligible if those first 3 patients do not experience dose limiting toxicity considered to be primarily related to the EBVST or Nivolumab.

^ Patients with relapsed or refractory lymphoma who failed or are ineligible for an autologous hematopoietic cell transplantation are also eligible for this study.

And

• Hodgkin's lymphoma patients in second relapse or first relapse and refractory to at least two lines of salvage chemotherapy including Brentuximab Vedotin or primary refractory disease after at least two lines therapy or
• Non- Hodgkin's lymphoma patients in first relapse and/or refractory to at least one salvage chemotherapy or with primary refractory disease after at least two lines of therapy or in second or subsequent relapse or
• T/NK- or B lymphoproliferative disease in first relapse and/or refractory to at least one salvage chemotherapy or with primary refractory disease after at least two lines of therapy or in second or subsequent relapse
• EBV positive tumor
• Patients with life expectancy >/= 6 weeks.
• Patients with bilirubin less than or equal to 3x upper limit of normal
• AST less than or equal to 5x upper limit of normal
• Hgb more than 8.0 (may be a transfused value).
• Patients with a creatinine less than or equal to 2x upper limit of normal for age
• Pulse oximetry of more than 90% on room air
• Patients should have been off other investigational therapy for 4 weeks prior to entry in this study.
• Patients with a Karnofsky/Lansky score of >/= 60
• Recovered from acute toxic effects of prior chemotherapy at least one week before entering the study.
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.
• Informed consent explained to, understood and signed by patient/guardian. Patient/guardian given a copy of informed consent.

Exclusion criteria

PROCUREMENT Exclusion

• Active infection with HIV, HTLV, HBV, HCV (can be pending at this time)
• History of solid organ transplant

TREATMENT Exclusion

• Pregnant or lactating due to unknown effects of this therapy on a fetus or lactation
• Severe active intercurrent infection.
• Current use of systemic corticosteroids >0.5 mg/kg/day
• Currently receiving any investigational agents or radiotherapy within 4 weeks prior to entering the study.
• Patients with central nervous system involvement.
• History of allergic reactions attributed to nivolumab or any other checkpoint inhibitors.
• Uncontrolled autoimmune disease needing systemic steroids or steroid sparing agents except for hypothyroidism or type I diabetes.
• History of solid organ transplant
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Lipase more than 70U/ml